NCT05357911已完成1 期
A Phase I, Single-center, Open-label, Fixed-sequence Study in Chinese Healthy Male Adults to Evaluate the Effect of AB-106 on the Pharmacokinetics of Digoxin
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- The PK exposure parameters of digoxin
研究概览
简要总结
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Chinese male healthy subjects (No clinical abnormality by medical history query, physical examination, vital signs, 12 lead ECG and clinical laboratory test)
- •Aged between 18 to 55 at giving written informed consent.
- •Body weight greater than 50.0 kg, and body mass index between 19 and 26 kg/m2, inclusive.
- •The subject is willing to give written informed consent.
- •The subject is capable to communicate well with investigator and comply with comply with protocol throughout the study.
- •For fertile males, agree to use effective contraception methods during the study intervention period and for at least 90 days after the last dose of investigational drug, and agree not to donate sperm during this period.
排除标准
- •Any presence or history of clinically significant hematology, nephrology, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, mental, neurological, or allergic diseases (including drug allergy).
- •Any clinically significant laboratory abnormality (hematology, biochemistry [fasting], urinalysis.)
- •systolic blood pressure (SBP) < 90 mmHg or ≥140 mmHg, diastolic blood pressure (DBP) < 50 mmHg or ≥ 90 mmHg, and clinically significant abnormality based on the judgment of investigators
- •Any presence or history of eye disease in whom the risk is increased by the participation to the study or treatment with investigational drug in the opinion of the investigator, such as glaucoma, retinal detachment, vitreous turbidity, and moths.
- •The 12-lead ECG showed QTcF > 450 milliseconds (msec) or QRS interval > 120 msec.
- •Fever within 5 days before the administration.
- •Active hepatitis B virus (HBV) surface antigen, hepatitis C virus antibody (HCV Ab), human immunodeficiency virus (HIV) or treponema pallidum (TP) antibody
- •Within 28 days prior to the first dose of study treatment, use of food or drugs that are known potent CYP3A4 inhibitors including (but not limited to) atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, aceto-eandomycin, voriconazole, grapefruit, grapefruit juice, grapefruit, citrus fruits or grapes Pomelo mixed species; or potent CYP3A4 inducers including (but not limited to) carbamazepine, phenobarbital, phenytoin, rifabutin, and rifampin and St. John's wort; or CYP3A4 substrates with narrow therapeutic window including (but not limited to)dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and terfenadine.
- •Within 28 days prior to the first dose of study treatment, use of food or drugs that are known p-gp substrates including (but not limited to) amiodarone, carvedilol, clarithromycin, dronedarone, itraconazole, lapatinib, lopinavir and ritonavir, propafenone, quinidine, ranolazine, Tonavir, Saquinavir and Ritonavir, Trapevir, Telanavir and Ritonavir, Verapamil.
- •Chinese herbal medicine or tonic must be withdrawn at least 28 days prior to the first dose of study treatment; Any clinical study drug is prohibited within 3 months or 5 half-lives prior to the first dose of investigational drug; Any prescription/over-the-counter drug/dietary supplement is prohibited within 14 days or 5 half-lives prior to the first dose of investigational drug; as an exception, acetaminophen/paracetamol can be used at a dose of 1 g/day.
- •Vaccinated with live or attenuated vaccine within 28 days prior to the first dose of study treatment
- •Subject is unwilling to withdraw foods containing caffeine or purines (such as coffee, tea, cola, chocolate) from 48h before first dose to finishing the last PK sample collection.
- •Alcohol intake is greater than 14 units/week (1 unit of alcohol is equivalent to 360 mL of beer, or 150 mL of wine, or 45 mL of baijiu), or subject is unwilling to withdraw alcohol from 48h before first dose to finishing the last PK sample collection.
- •Smoking more than 5 cigarette per day, or subject is unwilling to withdraw nicotine from 48h before first dose to finishing the last PK sample collection.
- •Any significant surgical history within 6 months prior to the first dose of study treatment.
- •Blood donation or blood loss ≥ 400 mL within 3 months or ≥ 200 mL within 1 month prior to the first dose of study treatment.
- •Presence of gastrointestinal, liver, kidney disease or other diseases or sequelae that are known to interfere with drug absorption, distribution, metabolism, or excretion. With a history of sensitivity to heparin or heparin-induced thrombocytopenia
- •Any drug abuse, or taking any soft drug (such as marijuana) or hard drugs (heroin, cocaine, etc.) from 1 year before and during the study period.
- •Unwilling or incapable to follow the lifestyle standard described in the protocol.
- •Staff members of any institution affiliated with the clinical site and their immediate family members. Immediate family members refer to persons with blood or legal relationship, including spouses, children, parents, and siblings.
- •Ineligible to participate in the study based on the judgement of investigators.
研究组 & 干预措施
digoxin cohort
Experimental
干预措施: AB-106, digoxin (Drug)
结局指标
主要结局
The PK exposure parameters of digoxin
时间窗: 17 days
Area under the plasma concentration versus time curve (AUC)
次要结局
- Safety assessment(35 days)
- The PK parameters of digoxin(17 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PKSolid TumorNCT05357820Nuvation Bio Inc.56
进行中（未招募）
2 期
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneNon Small Cell Lung CancerNCT04395677Nuvation Bio Inc.173
招募中
1 期
A Study in Patients With Advanced CancersAdvanced CancerAdvanced Solid TumorOncologyCancerNCT05320588BiOneCure Therapeutics Inc.332
招募中
1 期
ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaCarcinoma, HepatocellularNCT03897543Abivax S.A.48
撤回
1 期
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaMelanomaNCT02447939GlaxoSmithKline